Bayer Sees Light At End Of Consumer Turnaround Tunnel: Q3 Sales Grow 3.7%

Bayer consumer health segment shows 3.7% growth to $1.43bn on 9% growth in pain relief and 6.4% in allergy and cold. But North American business still faces challenges.

Inscription "Q3" on PC screen. Financial data on background.

Bayer AG’s OTC pain relief category had sales growth of 9% in the third quarter and its allergy and cold segment's sales increased 6.4% as its consumer health business shows some recovery while it continues implementing turnaround strategies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Euro Q1 Consumer Health Earnings Preview: Haleon, Reckitt, Bayer

 
• By 

Major Europe-based consumer health players Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q1 2025 results over the coming weeks.

Futura Records First Profits And Targets Eroxon Extension

 
• By 

The US launch of Eroxon ED treatment by Haleon helped Futura Medical record its first ever profit in 2024. The UK firm will now look to capitalize this by seeking US and EU approval for a more potent Eroxon line extension.

‘The Only Certainty Is Uncertainty’ In The UK’s Consumer Health Market

 
• By 

While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.

France’s Boiron Looks To Future After Challenging Year

 
• By 

The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.

More from Business

That Loud Noise Echoing In US OTC Hearing Aid Market? Merger Of Eargo And HearX

 

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

People On The Move: Appointments At Maxwellia, Nestlé, Alland & Robert

 
• By 

A round-up of the latest European health & wellness market moves: Maxwellia names chief operating officer; Nestle appoints marketing & sales head; Alland & Robert gets deputy general manager.

Pharma Still Nervous While Riding Trump’s Tariff Rollercoaster

 

The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.